Coherus BioSciences Company Profile (NASDAQ:CHRS)

About Coherus BioSciences

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Exchange: NASDAQ
• Symbol: CHRS
• CUSIP:

Key Metrics:

• Previous Close: $30.92
• 50 Day Moving Average: $30.051
• 200 Day Moving Average: $22.507
• 52-Week Range: $12.04 - $31.98
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -5.92
• P/E Growth: 0.000
• Market Cap: $1.34B
• Outstanding Shares: 43,380,000
• Beta: 5.27

Profitability:

• Net Margins: -591.61%
• Return on Equity: -1,583.92%
• Return on Assets: -116.18%

Debt:

• Debt-to-Equity Ratio: -1.61%
• Current Ratio: 2.19%
• Quick Ratio: 2.19%

Additional Links:

• Visit Coherus BioSciences' Official Website
• View CHRS on Google Finance
• View CHRS on Yahoo Finance
• View CHRS's Company Profile on Reuters
• Search for Coherus BioSciences Inc. on Google

Companies Related to Coherus BioSciences:

• Wright Medical Group (NASDAQ:WMGI)
• Insulet Corp. (NASDAQ:PODD)
• Nektar Therapeutics (NASDAQ:NKTR)
• Allscripts Healthcare Solutions (NASDAQ:MDRX)
• Radius Health (NASDAQ:RDUS)
• LifePoint Hospitals (NASDAQ:LPNT)
• Penumbra (NYSE:PEN)
• INC Research Holdings (NASDAQ:INCR)
• Team Health Holdings (NYSE:TMH)
• Ligand Pharmaceuticals (NASDAQ:LGND)

Earnings

Earnings History for Coherus BioSciences (NASDAQ:CHRS)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
11/7/2016
8/9/2016	Q2	($1.32)	($1.72)	$6.87 million	$14.07 million	View	Listen
5/9/2016	Q1	($1.42)	($1.67)			View	Listen
2/29/2016	Q4	($1.74)	($1.35)			View	Listen
11/9/2015	Q3		($1.86)	$16.10 million	$7.20 million	View	Listen
8/10/2015	Q215		($1.56)	$488.15 million		View	Listen
5/11/2015	Q115		($1.22)	$488.15 million		View	Listen
3/23/2015	Q414	($0.46)	($1.47)		$6.50 million	View	Listen
12/15/2014	Q212		($1.79)		$16.10 million	View	N/A
3/27/2012		($0.02)	($0.06)			View	N/A
12/1/2011		($0.09)	($0.08)			View	N/A
9/1/2011		$0.01	($0.01)			View	N/A
6/2/2011		$0.12	$0.17			View	N/A
3/24/2011		($0.19)	($0.08)			View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)

Dividends

Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Coherus BioSciences (NASDAQ:CHRS)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
9/21/2016	Dennis M Lanfear	Insider	Sell	4,060	$31.75	$128,905.00
9/16/2016	Dennis M Lanfear	Insider	Sell	2,900	$31.79	$92,191.00
8/8/2016	Fmr Llc	Insider	Sell	100,000	$29.86	$2,986,000.00
8/5/2016	Fmr Llc	Insider	Sell	48,600	$28.48	$1,384,128.00
8/1/2016	Alan C Herman	Insider	Sell	11,333	$25.54	$289,444.82
7/21/2016	Peter K Watler	Insider	Sell	3,991	$26.13	$104,284.83
7/20/2016	Peter K Watler	Insider	Sell	73,741	$25.02	$1,844,999.82
7/11/2016	Peter K Watler	Insider	Sell	43,495	$20.02	$870,769.90
7/1/2016	Alan C Herman	Insider	Sell	4,250	$16.89	$71,782.50
6/1/2016	Alan C Herman	Insider	Sell	4,250	$18.67	$79,347.50
5/17/2016	Peter K Watler	Insider	Sell	12,000	$20.00	$240,000.00
5/2/2016	Alan C Herman	Insider	Sell	4,250	$19.20	$81,600.00
2/5/2016	Alan C Herman	Insider	Sell	2,000	$15.02	$30,040.00
12/1/2015	Alan C. Herman	insider	Sell	11,333	$29.49	$334,210.17
11/13/2015	Christos Richards	Director	Sell	15,000	$27.49	$412,350.00
11/2/2015	Alan C. Herman	insider	Sell	18,416	$28.71	$528,723.36
10/1/2015	Alan C. Herman	insider	Sell	4,250	$18.98	$80,665.00
9/1/2015	Alan C. Herman	insider	Sell	11,333	$27.39	$310,410.87
8/18/2015	Mats Wahlstrom	Director	Sell	6,373	$33.50	$213,495.50
8/17/2015	Mats Wahlstrom	Director	Sell	8,028	$33.91	$272,229.48
8/14/2015	Mats Wahlstrom	Director	Sell	116,554	$34.24	$3,990,808.96
6/15/2015	August J Troendle	Director	Sell	250,000	$26.68	$6,670,000.00
11/12/2014	Eli & Co Lilly	Insider	Buy	164,963	$13.50	$2,227,000.50

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Coherus BioSciences (NASDAQ:CHRS)

Date	Headline
	Coherus BioSciences Regains Development and Commercial Rights to CHS-0214 From Shire (NASDAQ:CHRS) www.publicnow.com - September 27 at 8:47 AM
	COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ (NASDAQ:CHRS) biz.yahoo.com - September 26 at 4:26 PM
	Coherus BioSciences : Management to Present at Two Investor Healthcare Conferences in September (NASDAQ:CHRS) www.4-traders.com - September 24 at 8:27 AM
	News review of 2 biotech stocks: Coherus Biosciences, Inc. (NASDAQ:CHRS), Inovio Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:CHRS) voiceregistrar.com - September 21 at 8:15 AM
	ETF’s with exposure to Coherus BioSciences, Inc. : September 19, 2016 (NASDAQ:CHRS) www.capitalcube.com - September 19 at 5:00 PM
	Notable Friday Option Activity: CHRS, TWTR, PBYI - Forbes (NASDAQ:CHRS) www.forbes.com - September 18 at 8:54 AM
	AbbVie's Battle Royale (NASDAQ:CHRS) www.thestreet.com - September 14 at 8:27 AM
	The Sell-side Consensus is in on Coherus BioSciences, Inc. (NASDAQ:CHRS); Earnings & Target Updates - National Daily Press (NASDAQ:CHRS) www.nationaldailypress.com - September 9 at 9:01 AM
	Placing Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Under the Microscope - Post News (NASDAQ:CHRS) www.kentuckypostnews.com - September 8 at 5:34 AM
	Trading the Biotech News: Coherus Biosciences, Inc. (NASDAQ:CHRS), Ophthotech Corporation (NASDAQ:OPHT) - The Voice Registrar (NASDAQ:CHRS) voiceregistrar.com - September 7 at 9:16 PM
	Coherus BioSciences Announces New Employment Inducement Grants - GlobeNewswire (press release) (NASDAQ:CHRS) globenewswire.com - September 2 at 4:01 PM
	Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September (NASDAQ:CHRS) www.publicnow.com - September 1 at 4:07 PM
	3 Biotech Biosimilar Winners (NASDAQ:CHRS) blogs.barrons.com - September 1 at 4:07 PM
	Coherus BioSciences Announces New Employment Inducement Grants (NASDAQ:CHRS) www.publicnow.com - September 1 at 12:20 PM
	ETF’s with exposure to Coherus BioSciences, Inc. : August 29, 2016 (NASDAQ:CHRS) www.capitalcube.com - August 29 at 3:35 PM
	Is it Time to Buy Coherus BioSciences, Inc. (NASDAQ:CHRS)? Crowd & Analysts Weigh in - Post News (NASDAQ:CHRS) www.kentuckypostnews.com - August 24 at 11:00 AM
	COHERUS BIOSCIENCES, INC. Financials (NASDAQ:CHRS) finance.yahoo.com - August 18 at 4:14 PM
	ETF’s with exposure to Coherus BioSciences, Inc. : August 15, 2016 (NASDAQ:CHRS) www.capitalcube.com - August 15 at 11:27 AM
	Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:CHRS) www.capitalcube.com - August 12 at 11:49 AM
	Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food ... (NASDAQ:CHRS) www.nasdaq.com - August 10 at 10:25 PM
	Analyst Ratings Worth Watching: Coherus Biosciences Inc ... - Review Fortune (NASDAQ:CHRS) reviewfortune.com - August 10 at 10:46 AM
	EARNINGS SUMMARY: Details of Coherus Biosciences, Inc. Q2 Earnings Report (NASDAQ:CHRS) www.rttnews.com - August 9 at 10:00 PM
	Coherus BioSciences (CHRS) Announces CHS-1420 Phase 3 Met Primary Endpoint (NASDAQ:CHRS) www.streetinsider.com - August 9 at 10:00 PM
	Coherus BioSciences reports 2Q loss (NASDAQ:CHRS) sg.finance.yahoo.com - August 9 at 10:00 PM
	Commit To Purchase Coherus BioSciences At $20, Earn 9% Annualized Using Options (NASDAQ:CHRS) www.nasdaq.com - August 9 at 4:30 PM
	Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar… (NASDAQ:CHRS) forextv.com - August 9 at 4:30 PM
	Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration … (NASDAQ:CHRS) finance.yahoo.com - August 9 at 4:30 PM
	Coherus BioSciences (CHRS) Announces Submission of CHS-1701 BLA to U.S. FDA Under 351(k) Pathway (NASDAQ:CHRS) www.streetinsider.com - August 9 at 4:30 PM
	Coherus BioSciences Inc.: Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:CHRS) www.twst.com - August 9 at 4:30 PM
	Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:CHRS) www.publicnow.com - August 9 at 4:30 PM
	Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:CHRS) biz.yahoo.com - August 9 at 4:30 PM
	Coherus Biosciences Inc (NASDAQ:CHRS): Check on Earnings - Post Registrar (NASDAQ:CHRS) postregistrar.com - August 9 at 12:01 PM
	Coherus BioSciences (CHRS) Announces CHS-1420 Phase 3 Met Primary Endpoint - StreetInsider.com (NASDAQ:CHRS) www.streetinsider.com - August 9 at 12:01 PM
	Q2 2016 Coherus BioSciences Inc Earnings Release - After Market Close (NASDAQ:CHRS) biz.yahoo.com - August 9 at 12:01 PM
	Coherus Announces Positive Results For CHS-1420 In Patients With Psoriasis (NASDAQ:CHRS) www.nasdaq.com - August 8 at 8:59 AM
	Coherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis (NASDAQ:CHRS) www.publicnow.com - August 8 at 8:59 AM
	Coherus BioSciences, Inc. (CHRS) Updated Price Targets - FTSE News (NASDAQ:CHRS) www.ftsenews.co.uk - August 5 at 4:14 PM
	Citigroup Initiates Coverage on Coherus Biosciences Inc to Buy ... - Trade Calls (NASDAQ:CHRS) www.tradecalls.org - August 3 at 4:17 PM
	Brokers Issue Average Price Target Of 37.40 On Coherus BioSciences, Inc. (CHRS) - FTSE News (NASDAQ:CHRS) www.ftsenews.co.uk - July 29 at 9:40 PM
	Citi Analyst Sees 45-60% Upside In Coherus Biosciences (NASDAQ:CHRS) www.benzinga.com - July 27 at 12:49 PM
	Coverage initiated on Coherus BioSciences by Citigroup (NASDAQ:CHRS) finance.yahoo.com - July 27 at 6:36 AM
	Coherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th (NASDAQ:CHRS) www.publicnow.com - July 25 at 11:18 AM
	Checking in on Stock Volatility for: Coherus Biosciences, Inc. (NASDAQ:CHRS) - Engelwood Daily (NASDAQ:CHRS) www.engelwooddaily.com - July 22 at 4:15 PM
	Coherus Biosciences Inc on Focus After Crashing In Today's Session - Consumer Eagle (NASDAQ:CHRS) www.consumereagle.com - July 22 at 4:15 PM
	Equity Roundup: Stock Performance Focus on Coherus BioSciences, Inc. (NASDAQ:CHRS) - Press Telegraph (NASDAQ:CHRS) presstelegraph.com - July 22 at 4:15 PM
	Coherus BioSciences, Inc. (NASDAQ:CHRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:CHRS) www.engelwooddaily.com - July 22 at 4:15 PM
	Earnings Focus and Crowd Sourced Sentiment Review for Coherus BioSciences, Inc. (NASDAQ:CHRS) - TGP (NASDAQ:CHRS) telanaganapress.com - July 21 at 7:01 AM
	Coherus Biosciences Inc Just Recorded A Sigfniciant Increase - Press Telegraph (NASDAQ:CHRS) presstelegraph.com - July 21 at 7:01 AM
	Shares Jumping Higher in Session: Coherus Biosciences, Inc. (NASDAQ:CHRS) - TGP (NASDAQ:CHRS) telanaganapress.com - July 20 at 5:21 PM
	Coherus Biosciences Incorporated (NASDAQ:CHRS) Sellers Increased By 2.15% Their Shorts - Consumer Eagle (NASDAQ:CHRS) www.consumereagle.com - July 20 at 12:14 PM

Social

Coherus BioSciences (NASDAQ:CHRS) Chart for Wednesday, September, 28, 2016